FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells

Biochemical Pharmacology

Volumn 81, Issue 7, 2011, Pages 848-855

  Wang, Qiang ^a   Liu, Xiaobing ^b   Wang, Qingduan ^c   Zhang, Yan ^c   Jiang, Jinhua ^c   Guo, Xiaohe ^d   Fan, Qingxia ^e   Zheng, Liyun ^c   Yu, Xuejun ^d   Wang, Ning ^c   Pan, Zhenliang ^a   Song, Chuanjun ^a   Qi, Wenqing ^b   Chang, Junbiao ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA   (United States)

^c Henan Academy of Medical and Pharmaceutical Sciences   (China)

^d Henan Academy of Science   (China)

^e THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; DNA synthesis; FNC; Nucleoside analogues; Tumor growth inhibition

Indexed keywords

4' AZIDO 2' DEOXYFLUOROARABINOCYTIDINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; FLUOROURACIL; NOCODAZOLE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; STOMACH CANCER; STOMACH SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIDES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; HUMANS; INHIBITORY CONCENTRATION 50; MICE;

EID: 79952574371     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.01.001     Document Type: Article

References (31)

1. Hoggard PG, Sales SD, Kewn S, Sunderland D, Khoo SH, Hart CA, et al. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. Antivir Chem Chemother 2000;11:353-8. (Pubitemid 32157254)
2. Wurtzer S, Compain S, Benech H, Hance AJ, Clavel F. Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1. J Virol 2005;79:14815-21. (Pubitemid 41636279)
3. Major PP, Egan EM, Herrick DJ, Kufe DW. Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol 1982;31:2937-40. (Pubitemid 12028583)
4. Ross DD, Cuddy DP. Consequences of 2′,2′- difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells. Semin Oncol 1995;22:26-34.
5. Bianchi V, Borella S, Rampazzo C, Ferraro P, Calderazzo F, Bianchi LC, et al. Cell cycle-dependent metabolism of pyrimidine deoxynucleoside triphosphates in CEM cells. J Biol Chem 1997;272:16118-24. (Pubitemid 27276425)
6. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980;255:8997-9900.
7. Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, et al. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ 1998;5:584-91. (Pubitemid 28356580)
8. Koo HM, McWilliams MJ, Alvord WG, Vande Woude GF. Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. Cancer Res 1999;59:6057-62.
9. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 28:418-23.
10. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14. (Pubitemid 29062965)
11. Sun D, Urrabaz R, Kelly S, Nguyen M, Weitman S. Enhancement of DNA ligase I level by gemcitabine in human cancer cells. Clin Cancer Res 2002;8:1189-95. (Pubitemid 35177374)
12. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998;78(Suppl. 3):1-7. (Pubitemid 128710590)
13. Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54:447-72.
14. Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002;100:334-40. (Pubitemid 35177465)
15. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 1990;265:16617-25.
16. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995;36:181-8.
17. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 1995;22:19-25.
18. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 2001;61:1065-72. (Pubitemid 32174426)
19. de Vries JF, Falkenburg JH, Willemze R, Barge RM. The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 2006;91:912-9. (Pubitemid 44023144)
20. Radosevic N, Delmer A, Tang R, Marie JP, Ajchenbaum-Cymbalista F. Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure. Leukemia 2001;15:559-66. (Pubitemid 32266722)
21. Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Bechet JM, Dusanter-Fourt I, et al. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 2004;104:2475-83. (Pubitemid 39331850)
22. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201-9. (Pubitemid 24378654)
23. da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Junior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 235:814-24.
24. (a). Chang J, Bao X, Wang Q, Guo X, Wang W, Qi X. Preparation of 2′-fluoro-4′-substituted nucleoside analogs as antiviral agents. Chinese Patent Application No: CN 2007-10137548, 20070807; Chinese Patent No: CN 101177442A, 20080514;
25. (b). Chang J. 2′-Fluoro-4′-substituted nucleosides, the preparation and use. International Application No: PCT/CN2008/001239, 20080627; International Patent No: WO2009009951, 20090122
26. (c). Chang J. 2′-Fluorine-4′-substituted nucleoside analogues, preparation methods and uses thereof. US Patent No: US 2010/0234584A1, 20100916
27. (d). Chang J, Wang Q, Wang Q. 2′-fluoro-4′-substituted nucleoside analogs and application. Chinese Patent Application No: CN 200910227556.3, Chinese Patent No: CN 201010506595X;
28. (e) Smith DB, Kalayanov G, Sund C, Winqvist A, Maltseva T, Leveque VJ, et al. The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4′-azidocytidine against hepatitis C virus replication: the discovery of 4′-azido-2′-deoxy-2′-fluorocytidine and 4′-azido-2′-dideoxy-2′,2′-difluorocytidine. J Med Chem 2009;52:2971-8.
29. Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, et al. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem 2008;283:2167-75.
30. Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M, et al. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 2005;92:681-9. (Pubitemid 40460604)
31. Ohrui H, Kohgo S, Hayakawa H, Kodama E, Matsuoka M, Nakata T, et al. 2′-Deoxy-4′-C-ethnyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma. Nucleic Acids Symposium Series, Oxford Univeristy Press, 2006;50:1-2.